MARKET

PEN

PEN

Penumbra Inc
NYSE
190.83
+4.54
+2.44%
After Hours: 190.83 +0.01 +0.01% 16:01 07/12 EDT
OPEN
187.44
PREV CLOSE
186.29
HIGH
194.58
LOW
187.44
VOLUME
389.98K
TURNOVER
0
52 WEEK HIGH
344.04
52 WEEK LOW
170.59
MARKET CAP
7.40B
P/E (TTM)
80.28
1D
5D
1M
3M
1Y
5Y
1D
Penumbra, Inc. (NYSE:PEN) Shares Could Be 23% Above Their Intrinsic Value Estimate
Penumbra, Inc. (NYSE:PEN) has been estimated to be 23% overvalued. Penumbra's estimated fair value is US$146 based on 2 Stage Free Cash Flow to Equity. The current share price of US$179 suggests PEN is potentially 23% above its fair value. We will use a discounted cash flow model to estimate the intrinsic value of PEN. The model is based on the expected future cash flows and discounted to their present value.
Simply Wall St · 3d ago
Penumbra Is Maintained at Buy by Citigroup
Dow Jones · 4d ago
Citigroup Maintains Buy on Penumbra, Lowers Price Target to $265
Benzinga · 4d ago
(PEN) - Analyzing Penumbra's Short Interest
Penumbra's short percent of float has risen 7.33% since its last report. The company has 2.37 million shares sold short, which is 8.64% of all regular shares available for trading. Short interest is the number of shares that have been sold short but are not yet covered. Short selling is when a trader sells shares with the hope that the price will fall.
Benzinga · 4d ago
Here's Why Holding Align Technology (ALGN) Stock Could Pay Off
NASDAQ · 5d ago
Weekly Report: what happened at PEN last week (0701-0705)?
Weekly Report · 6d ago
Inari Medical: A Touch Of Uncertainty And Overvaluation
Inari Medical, Inc. Is a leader in the venous thromboembolism space. The company's stock is down over 20% in 2024 due to a recent DOJ probe. Inari Medical should achieve sustainable profitability in 2025. The medical device maker is seeing solid revenue growth and upped guidance for FY2024.
Seeking Alpha · 07/05 18:58
Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024
Penumbra, Inc. Will host a conference call to discuss financial results for the second quarter 2024 after market close on Tuesday, July 30, 2024 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone or on the company's website.
PR Newswire · 07/02 20:05
More
About PEN
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Webull offers Penumbra Inc stock information, including NYSE: PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.